Skip to main content

Table 1 Overview of the NP properties

From: Encapsulation of the dual FLAP/mPEGS-1 inhibitor BRP-187 into acetalated dextran and PLGA nanoparticles improves its cellular bioactivity

NP formulationAfter purificationAfter lyophilizationEE (%)LC (%)PVA (%)
dH (nm)PDIdH (nm)PDIζ (mV)
Acdex210 ± 260.17 ± 0.07211 ± 350.26 ± 0.09− 12 ± 20.01 ± 0.000
Acdex[BRP-187]196 ± 510.16 ± 0.11178 ± 260.13 ± 0.07− 13 ± 859 ± 231.7 ± 0.60.01 ± 0.000
Acdex-RhodB[BRP-187]163 ± 150.20 ± 0.06189 ± 370.28 ± 0.11− 24 ± 267 ± 102.0 ± 0.3n.m.
PLGA124 ± 60.06 ± 0.03130 ± 20.09 ± 0.03− 20 ± 20.02 ± 0.002
PLGA[BRP-187]153 ± 410.17 ± 0.14158 ± 350.12 ± 0.06− 15 ± 376 ± 222.2 ± 0.60.03 ± 0.002
PLGA-DY635143 ± 30.08 ± 0.03154 ± 50.15 ± 0.02− 20 ± 10.02 ± 0.006
PLGA-DY635[BRP-187]153 ± 20.12 ± 0.01168 ± 90.19 ± 0.05− 19 ± 187 ± 62.5 ± 0.20.02 ± 0.002
  1. Concentration of NPs used for the PVA assay was 3 mg mL−1. SD for all measurements n ≥ 3. n.m.–not measured
  2. dH Hydrodynamic diameter obtained by DLS measurements. EE encapsulation efficiency. LC loading capacity